Hims & Hers Health, Inc. (NYSE:HIMS) Receives $21.43 Consensus Price Target from Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has been given a consensus recommendation of “Hold” by the seventeen brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $22.80.

HIMS has been the topic of several recent research reports. Morgan Stanley started coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target on the stock. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total value of $47,738.99. Following the transaction, the insider now owns 172,274 shares in the company, valued at approximately $3,516,112.34. This represents a 1.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the sale, the insider now owns 193,980 shares of the company’s stock, valued at $4,306,356. This trade represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,085,157 shares of company stock worth $26,765,193. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC raised its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $111,000. Finally, Quarry LP grew its position in Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after buying an additional 2,913 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 0.6 %

NYSE:HIMS opened at $26.20 on Monday. Hims & Hers Health has a 1 year low of $8.09 and a 1 year high of $35.02. The stock has a 50-day moving average price of $25.78 and a two-hundred day moving average price of $21.27. The stock has a market cap of $5.72 billion, a price-to-earnings ratio of 59.55 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the business earned ($0.04) EPS. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. Sell-side analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.